AxoGen SEC Filings

Type
Report
Date
4Insidertransaktion3/2/2026
4Insidertransaktion3/2/2026
4Insidertransaktion3/2/2026
4Insidertransaktion2/27/2026
4Insidertransaktion2/27/2026
4Insidertransaktion2/24/2026
10-KJahresbericht2/24/2026
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben2/24/2026
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben1/23/2026
424B5424B5-Formular1/23/2026
424B5424B5-Formular1/21/2026
S-3ASRS-3ASR-Formular1/21/2026
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben1/12/2026
4Insidertransaktion12/17/2025
4Insidertransaktion12/17/2025
4Insidertransaktion12/17/2025
144144-Formular12/16/2025
144144-Formular12/16/2025
144144-Formular12/15/2025
4Insidertransaktion12/12/2025
4Insidertransaktion12/12/2025
144144-Formular12/11/2025
4Insidertransaktion12/10/2025
4Insidertransaktion12/10/2025
4Insidertransaktion12/10/2025
4Insidertransaktion12/10/2025
4Insidertransaktion12/10/2025
4Insidertransaktion12/10/2025
4Insidertransaktion12/10/2025
4Insidertransaktion12/10/2025
144144-Formular12/10/2025
144144-Formular12/9/2025
144144-Formular12/9/2025
144144-Formular12/9/2025
144144-Formular12/8/2025
144144-Formular12/8/2025
4Insidertransaktion12/5/2025
4Insidertransaktion12/5/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben12/5/2025
4Insidertransaktion12/5/2025
4Insidertransaktion12/5/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben12/4/2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular11/14/2025
4Insidertransaktion11/13/2025
144144-Formular11/12/2025
144144-Formular11/10/2025
4Insidertransaktion11/7/2025
144144-Formular11/6/2025
144144-Formular11/5/2025
4Insidertransaktion10/31/2025
144144-Formular10/30/2025
144144-Formular10/29/2025
10-QQuartalsbericht10/29/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben10/29/2025
4Insidertransaktion10/24/2025
144144-Formular10/22/2025
4Insidertransaktion10/7/2025
4Insidertransaktion10/6/2025
144144-Formular10/6/2025
144144-Formular10/3/2025
144144-Formular10/3/2025
144144-Formular10/2/2025
144144-Formular10/2/2025
4Insidertransaktion9/16/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben8/25/2025
S-8S-8-Formular8/5/2025
10-QQuartalsbericht8/5/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben8/5/2025
4Insidertransaktion6/20/2025
4Insidertransaktion6/20/2025
4Insidertransaktion6/20/2025
4Insidertransaktion6/20/2025
4Insidertransaktion6/20/2025
4Insidertransaktion6/20/2025
4Insidertransaktion6/20/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben6/20/2025
4Insidertransaktion6/11/2025
4Insidertransaktion6/11/2025
4Insidertransaktion6/11/2025
4Insidertransaktion6/11/2025
4Insidertransaktion6/11/2025
4Insidertransaktion6/11/2025
4Insidertransaktion6/11/2025
144144-Formular6/10/2025
4Insidertransaktion5/23/2025
4Insidertransaktion5/23/2025
144144-Formular5/22/2025
33-Formular5/16/2025
4Insidertransaktion5/16/2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular5/15/2025
10-QQuartalsbericht5/8/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben5/8/2025
SCHEDULE 13G/ASCHEDULE 13G/A-Formular5/2/2025
ARSARS-Formular4/30/2025
DEF 14ADEF 14A-Formular4/30/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben4/7/2025
4Insidertransaktion3/26/2025
4Insidertransaktion3/26/2025
4Insidertransaktion3/26/2025
4Insidertransaktion3/26/2025

AxoGen Documents 2026

This page contains all official documents and SEC filings for AxoGen stock (AXGN, ISIN: US05463X1063). This includes annual reports (Form 10-K), quarterly reports (Form 10-Q), and insider transactions (Form 4). Currently 100 documents are available. Data is updated regularly to provide investors with a complete overview of AxoGen's regulatory filings.

AxoGen Stock analysis

AxoGen AxoGen Inc is a US-American company based in Alachua, Florida. The company was founded in 2002 as a spin-off of the Grabowski Laboratory at the University of Florida. The goal of the company is to improve the regeneration of peripheral nerves through innovative products and solutions. AxoGen's business model is based on the development, production, and sale of biomaterial-based products for peripheral nerve regeneration. The company has three product categories: Avance nerve tissue, AxoGuard nerve wraps, and AxoTouch nerve testers. Avance nerve tissue is a proven technology for improving the regeneration of peripheral nerves. It consists of allogeneic nerve tissue from donors that has been prepared and sterilized for transplantation. Avance nerve tissue is used for surgical repair of nerve damage and has proven to be very effective in regenerating peripheral nerves. AxoGuard nerve wraps are silicone gels used for repairing nerve damage. They protect the delicate nerve fibers during the healing process and prevent scar formation. AxoGuard nerve wraps were designed to preserve the structure and function of nerves after surgical repair. AxoTouch nerve testers are devices used to measure nerve function. They are used to monitor and evaluate the integrity and function of peripheral nerves. This system is of great importance for assessing the surgical repair of nerve damage and monitoring the progress of healing. In recent years, AxoGen has experienced significant growth and has become a leading company in the field of peripheral nerve regeneration. The company has offices in the US and Europe and distributes its products worldwide. AxoGen is listed on the NASDAQ stock exchange and has a market capitalization of approximately $2.3 billion. AxoGen has made significant progress in recent years and has achieved several important milestones. In 2012, the company received approval from the US Food and Drug Administration (FDA) for the use of Avance nerve tissue for surgical repair of nerve damage. In 2014, AxoGen received CE marking for Avance nerve tissue and AxoGuard nerve wraps, thereby obtaining approval for the European market. AxoGen is continuously working on the development of new products and solutions to improve nerve regeneration. The company has a strong scientific foundation and is heavily involved in research. AxoGen also collaborates with leading scientists and clinics to improve its products and develop new applications. In summary, AxoGen is an innovative company specializing in the development and production of biomaterial-based products for peripheral nerve regeneration. The company has become a market leader in recent years and operates worldwide. AxoGen has brought proven technologies and products to the market that help improve nerve regeneration and enhance patients' quality of life.